AB0577 β2-Microglobulin as a Marker of Disease Activity in Systemic Lupus Erythematosus. (9th June 2015)

• Record Type: Journal Article
• Authors: Żychowska, I.; Suszek, D.; Dryglewska, M.; Majdan, M.
• Is Part Of: Annals of the rheumatic diseases. Volume 74(2015)Supplement 2
• Page Start: 1093
• Page End: 1093
• Publication Date: 2015-06-09
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2015-eular.3325
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Estimating of Systemic Lupus Erythematosus (SLE) activity is necessary for the choice of correct treatment and for monitoring its results. There are many tools for assessment of SLE activity. Clinical methods including the assessment of numerous organs' involvement and concentration of marker proteins are useful. There are ongoing studies concerning the usefulness of new biochemical markers which correlate with the clinical symptoms and other disease activity indicators. It has been suggested recently in the literature, that such role could be played by β2-microglobulin (β2M) serum concentration. Objectives: The aim of this study was to investigate the relationship between serum levels of β2M and clinical, immunological markers of disease activity in SLE patients (pts). Methods: Sixty-nine SLE pts (62 female; 7 men), aged 34.5±11.5 years (range 19-69) with duration of the disease of 5.8±4.8 years (0.5-19) were included. The level of β2M was investigated by enzyme-linked immunosorbent assay. Disease activity was assessed by: SLEDAI-2K, circulating levels of complement C3, C4, anti-double-stranded DNA (anti-DNA) and serum levels of β2M. We also estimated the relationship between serum levels of β2M and clinical manifestations of SLE. Results: Median serum levels of β2M were 3.0±1.2 μg/ml (1.8-8.6) in SLE pts. Serum levels of β2MG were positive in 24 SLE pts (34.8%). The significant correlations were found between serum levels of β2M and of anti-dsDNA (p=0.04; r=0.26), C3 complement (p=0.02; r= -0.3) and SLEDAI-2K (p=0.0005; r=0.64). The SLE pts with arthritis, vasculitis and hematologic symptoms had significantly higher β2M levels than those without, respectively. Conclusions: Serum level of β2M can be a good biochemical marker of the activity of SLE, positively correlated with clinical activity of the disease. References: Kim HA, Jeon JY, Yoon JM, Suh CH. Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci. 2010 Apr;339(4):337-340. Hermansen ML, Hummelshøj L, Lundsgaard D, Hornum L, Keller P, Fleckner J, Fox B, Poulsen LK, Jacobsen S. Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus. Lupus.(2012) 21, 1098-1104. Wakabayashi K, Inokuma S, Matsubara E, Onishi K, Asashima H, Nakachi S, Hagiwara K. Serum β2-microglobulin level is a useful indicator of disease activity and hemophagocytic syndrome complication in systemic lupus erythematosus and adult-onset Still's disease. Clin Rheumatol. 2013 Jul;32(7):999-1005. Skare TL, Ferri K, Santos MA. Systemic lupus erythematosus activity and beta two microglobulin levels. Sao Paulo Med J. 2014;132(4):239-42. Disclosure of Interest: None declared